DelveInsight’s, “Natural Killer Cell Therapies Pipeline Insight 2025” report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Natural Killer (NK)-Cell Lymphoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Natural Killer (NK)-Cell Lymphoma Pipeline Outlook
Key Takeaways from the Natural Killer (NK)-Cell Lymphoma Pipeline Report
Stay ahead with the most recent pipeline outlook for Natural Killer (NK)-Cell Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Natural Killer (NK)-Cell Lymphoma Treatment Drugs
Natural Killer (NK)-Cell Lymphoma Emerging Drugs Profile
Monalizumab (also known as IPH2201) is a first-in-class humanized IgG4 targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic NK and CD8 T lymphocytes. It is under development by Innate Pharma in Phase III stage for the treatment of Squamous Cell Carcinoma of the Head and Neck and in Phase II stage of development for the treatment of gynecological cancers, chronic lymphocytic leukemia, and head and neck cancer. It is in the Phase I stage of development for the treatment of advanced solid tumors and hematological malignancies.
NKTR-214 is designed to grow specific cancer-killing T-cells and natural killer cell populations in the body that fight cancer is known as endogenous tumor-infiltering lymphocytes (TILs). NKTR-214 stimulates these cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and Natural Killer (NK) cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase the proliferation of these effector T cells.
ALT 803 is a novel IL-15 superagonist complex, with improved pharmacokinetic properties and enhanced anti-tumor activity compared to recombinant human IL-15. It has also shown to potently activate human effector NK cells and enhance antibody-dependent cell-mediated cytotoxicity (ADCC) of anti-CD20 antibodies against human lymphoma cells in various tumor models. It is under development by Altor Bioscience Corporation and is currently in Phase II/III for Bladder Cancer. It is in Phase II stage for the treatment of Acute Myelogenous Leukemia (AML); Non-muscle Invasive Blood Cancer, in Phase I/II stage for the treatment of Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndromes (MDS); Multiple Myeloma; Advanced Pancreatic Cancer; Non-small Cell Lung Cancer and Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma. It is in Phase I stage for the treatment of Human Immunodeficiency virus (HIV) and Melanoma, Renal Cell, and Squamous Cell Head and Neck Cancer. It is developed by using IL-15 Protein Super agonist and Scaffold Technology and is administered by intravenous route.
ALECSAT (Autologous Lymphoid Effector Cells Specific against Tumor-cells) is a therapy that supplements and strengthens the patient’s immune system so it can fight the cancer cells in the same way as the body originally should have reacted. Natural Killer Cells used, in the ALECSAT therapy attack, the cancer cells in several ways, as they can recognize more than one property of the cancer cells. ALECAST is being evaluated for breast cancer and newly diagnosed glioblastoma in Phase II.
PNK-007 is a human umbilical cord blood-derived, culture-expanded natural killer cell therapy. The umbilical cord has CD34+ cells that are differentiated and expanded up to 50,000 fold over 35 days in a good manufacturing process (GMP) compliant facility to produce 12 billion cells that are 85% pure for NK cells without the use of a feeder cell line. These cells can be aliquoted and frozen for use at a later date. The CDK derived NK cells have substantial cytolytic activity against several human tumor cell lines, primary AML, and primary multiple myeloma cells. PNK-007 successfully completed pre-clinical studies for acute myeloid leukemia (AML) and multiple myeloma (MM) and is being evaluated in Phase I for the treatment of acute myeloid leukemia and Glioblastoma. PNK-007 is administered intravenously and developed by Cellular Therapeutics.
The Natural Killer (NK)-Cell Lymphoma Pipeline Report Provides Insights into
Explore groundbreaking therapies and clinical trials in the Natural Killer (NK)-Cell Lymphoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Natural Killer (NK)-Cell Lymphoma Drugs
Natural Killer (NK)-Cell Lymphoma Companies
ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, and Kuur Therapeutics (Formerly Cell Medica) and others.
Natural Killer Cell Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Natural Killer (NK)-Cell Lymphoma Products have been categorized under various Molecule types such as
Unveil the future of Natural Killer (NK)-Cell Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Natural Killer (NK)-Cell Lymphoma Market Drivers and Barriers
Scope of the Natural Killer (NK)-Cell Lymphoma Pipeline Report
Get the latest on Natural Killer (NK)-Cell Lymphoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Natural Killer (NK)-Cell Lymphoma Companies, Key Products and Unmet Needs
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight
